β‐Catenin alterations in testicular Leydig cell tumour: a immunohistochemical and molecular analysis
Histopathology · 2024
DOI: 10.1111/his.15175 ↗Kurz gefasst
Fachartikel in der Zeitschrift Histopathology, 2024. Verfasst von Yukiko Kitagawa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Indiana University, Indianapolis, IN, USA. Hauptthemen laut MEDLINE: beta Catenin, Testicular Neoplasms, Leydig Cell Tumor, Immunohistochemistry. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Testicular Leydig cell tumours (LCTs) are the most common type of sex cord–stromal tumour in men, representing 1%–3% of all testicular neoplasms. Among testicular sex cord–stromal tumours, CTNNB1 mutations and nuclear expression of β‐catenin have been typically associated with Sertoli cell tumour. Recent genomic analyses have shown that CTNNB1 variants are also identified in a subset of LCTs; however, the frequency and clinicopathologic associations of β‐catenin alterations remain incompletely understood in this tumour type.
Methods
In this study, we evaluated 32 LCTs (five malignant/metastasizing, 27 nonmetastasizing) using β‐catenin immunohistochemistry and DNA sequencing.
Results
Immunohistochemistry revealed focal or multifocal nuclear β‐catenin expression in 47% of the tumours. Diffuse nuclear β‐catenin expression (in >50% of the tumour cells) was not detected in any of the cases analysed herein. Comparison of β‐catenin‐positive and β‐catenin‐negative cases did not show significant differences in the frequency of adverse histopathologic findings or malignant clinical behaviour. DNA sequencing performed de novo on a subset of seven cases revealed the presence of exon 3 CTNNB1 variants in four of them (4/7, 57%), with variant allele frequencies (VAF) ranging from 7 to 33%. Two additional β‐catenin‐positive cases that had been sequenced as part of a previous study harboured exon 3 CTNNB1 variants at VAF of 28% and 7%, respectively.
Conclusion
These results demonstrate that β‐catenin alterations are relatively common in LCT, most likely occurring as subclonal events that are not enriched in cases with aggressive features. Further studies are needed to clarify the oncogenic role of β‐catenin in this tumour type.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Indiana University, Indianapolis, IN, USA.
- Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Department of Pharmacy and Biotechnology (FaBit), University of Bologna, Bologna, Italy.
- DIAP-Dipartimento InterAziendale di Anatomia Patologica di Bologna, Maggiore Hospital, Bologna, Italy.
- Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
- Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
ORCID-Profile: Katrina Collins, Muhammad T Idrees, Andres Martin Acosta
Zitieren
APA
Kitagawa, Y., De Biase, D., Ricci, C., Cornejo, K. M., Fiorentino, M., Collins, K., Idrees, M. T., Colecchia, M., Ulbright, T. M., & Acosta, A. M. (2024). β‐Catenin alterations in testicular Leydig cell tumour: a immunohistochemical and molecular analysis. Histopathology. https://doi.org/10.1111/his.15175
Vancouver
Kitagawa Y, De Biase D, Ricci C, Cornejo KM, Fiorentino M, Collins K, et al. β‐Catenin alterations in testicular Leydig cell tumour: a immunohistochemical and molecular analysis. Histopathology. 2024. doi:10.1111/his.15175
BibTeX
@article{Kitagawa2024,
author = {Kitagawa, Yukiko and De Biase, Dario and Ricci, Costantino and Cornejo, Kristine M and Fiorentino, Michelangelo and Collins, Katrina and Idrees, Muhammad T and Colecchia, Maurizio and Ulbright, Thomas M and Acosta, Andres Martin},
title = {β‐Catenin alterations in testicular Leydig cell tumour: a immunohistochemical and molecular analysis},
journal = {Histopathology},
year = {2024},
doi = {10.1111/his.15175}
}
EUVIMED